Lanean...
Colorectal Cancer Biomarkers in the Era of Personalized Medicine
The 5-year survival probability for patients with metastatic colorectal cancer has not drastically changed over the last several years, nor has the backbone chemotherapy in first-line disease. Nevertheless, newer targeted therapies and immunotherapies have been approved primarily in the refractory s...
Gorde:
| Argitaratua izan da: | J Pers Med |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6463111/ https://ncbi.nlm.nih.gov/pubmed/30646508 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm9010003 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|